Latest / Investor Exchange / AsiaMedic's Profit Leaps S$2M In FY2025

Transcript

AsiaMedic's Profit Leaps S$2M In FY2025 · Investor Exchange

• 0:08
  Usually when a company announces that their profits just doubled,
• 0:12
  you naturally picture Scrooge McDuck, right?
• 0:15
  Like swimming in a giant vault of gold.
• 0:18
  Oh, absolutely. That is the standard investor fantasy. Right.
• 0:22
  But today we are looking at a Singaporean health care company that doubled its
• 0:26
  profits to two million dollars while its bank account actually shrank.
• 0:31
  Which is honestly the absolute definition of a financial puzzle. Yeah.
• 0:35
  How does a business make twice as much money but end up with less liquid cash?
• 0:40
  Well, the income statement shows this soaring profitability,
• 0:43
  but then the balance sheet tells a completely different story.
• 0:45
  And figuring out that puzzle is our mission for you today on The Deep Dive.
• 0:49
  We are looking closely at Asia Medic Limited. Specifically, we're diving into
• 0:53
  their full year 2025 press release and their condensed interim financial statements.
• 0:58
  Yeah, they are a catalyst-listed healthcare provider in Singapore.
• 1:03
  And our goal here is to strip away all the dense accounting jargon and analyze
• 1:07
  these documents purely from an investor's perspective.
• 1:10
  Which I think is an essential exercise. It is incredibly easy to just skim a
• 1:14
  headline that says, you know, profits doubled and make a snap judgment.
• 1:18
  Oh, for sure. People do it all the time. Right.
• 1:20
  But today is all about understanding the mechanics driving those numbers.
• 1:24
  We really want to look under the hood and figure out the why.
• 1:27
  Okay, let's untack this because they genuinely look fantastic on the surface.
• 1:31
  For the financial year 2025, Asia Medics total revenue was up 22%.
• 1:36
  Yeah, hitting S35.2 million dollars.
• 1:39
  But the profitability metrics are what really jump off the page.
• 1:42
  Their PTMI doubled to S2.0 million dollars.
• 1:47
  Now, before we go any further, could you translate that abbreviation for the listener? Oh, sure.
• 1:52
  So PTMI stands for Profit After Tax and Minority Interests.
• 1:55
  Okay, meaning what exactly? Meaning it's the pure actual profit that belongs
• 1:59
  strictly to the owners of the company after the tax man and any minority partners take their cut.
• 2:04
  Got it. So that true bottom line number doubled, and then there's the EBITDA.
• 2:08
  Right, EBITDA. That is earnings before interest, taxes, depreciation,
• 2:12
  and amortization. Which is a mouthful. It is, yeah.
• 2:16
  But simply put, it is a measure of the core operational profitability.
• 2:19
  It shows the cash-generating engine of the business before you factor in accounting noise.
• 2:24
  Like depreciation and financing costs, right? Exactly.
• 2:27
  And that metric jumped a substantial 60% to $5.6 million.
• 2:32
  A 60% jump in core operational profit is huge.
• 2:36
  So what is the engine driving that kind of growth?
• 2:41
  The primary driver is undeniably their diagnostic imaging segment.
• 2:45
  It grew by an impressive 45%. Wow.
• 2:48
  From what to what? Jumping from $15.9 million last year,
• 2:53
  to S$23.1 million this year. Okay, that's massive.
• 2:57
  Did they just see way more patients? Well, yeah. The growth was fueled by generally
• 3:01
  higher patient volumes across the board.
• 3:03
  But the real catalyst, the big engine here, was their newly expanded Diagnostic
• 3:08
  Imaging Center at Royal Square Medical Center, Novena.
• 3:11
  You know, looking at the trajectory of that Novena Center, it feels a lot like
• 3:14
  building a second runway at an airport.
• 3:16
  Oh, that's a good way to look at it. Right, like the concrete costs an absolute
• 3:19
  fortune, and you usually have to take on substantial debt just to pay the thing.
• 3:22
  Oh, millions of dollars. Easily. Exactly.
• 3:25
  But once the runway is actually built and the planes start landing,
• 3:28
  the marginal cost of routing one extra flight is tiny.
• 3:31
  That is a highly accurate way to visualize it. So that's what we are seeing here.
• 3:35
  The runway is built, the capacity is there, and now the flights are just compounding.
• 3:40
  Yes. And management actually notes that FY 2025 reflects this transition.
• 3:45
  Moving from an investment phase into an operational scaling phase.
• 3:48
  Because they poured all that capital into Novena over the last few years. Right.
• 3:52
  To secure the physical space and buy the high-tech machinery.
• 3:55
  And now, that expanded diagnostic capacity is finally ramping up.
• 4:00
  They're seeing the patients.
• 4:01
  Exactly. Seeing patients and dropping that revenue directly down to the bottom line.
• 4:05
  But I mean, operating a massive new runway means you need air traffic controllers,
• 4:09
  maintenance crews, you know, a whole lot of overhead. It's not free to run. Right.
• 4:14
  In the medical world, running expanded MRI and x-ray facilities means hiring highly trained staff.
• 4:20
  And looking at the expenses, the cost of this growth is certainly making its presence felt.
• 4:25
  Unquestionably. I mean, personnel expenses alone rose 12 percent to 16.1 million dollars.
• 4:32
  Which makes sense. Yeah. You cannot run new imaging machines without hiring
• 4:37
  additional doctors, radiographers and support staff.
• 4:40
  And didn't their facility costs jump too?
• 4:42
  They did. Facility and administrative costs jumped 45 percent.
• 4:47
  And perhaps most notably, their finance costs spiked by 61 percent.
• 4:52
  61 percent, up to $1.9 million.
• 4:55
  Right. And that is driven directly by the interest on the equipment financing
• 4:58
  and the lease liabilities for all that new medical technology. Right.
• 5:02
  Wait, I have to step in with some skepticism here. Go for it.
• 5:04
  If the costs of financing,
• 5:06
  housing, and staffing this brand-new medical center are rising so steeply,
• 5:11
  like personnel is up and finance costs spiked 61%, how on earth did their bottom-line
• 5:16
  profit still manage to double?
• 5:18
  It feels like the math shouldn't work. It really does.
• 5:21
  What's fascinating here is a highly specific, very important detail buried in
• 5:26
  the notes to the financial statements.
• 5:27
  Okay, what is it? It has to do with how they account for the wear and tear on their equipment.
• 5:31
  During the year, management actually reassessed the useful life of their medical
• 5:35
  equipment. Useful life, like how long the machines last? Exactly.
• 5:39
  They extended it from 10 years to 15 years. And they also extended the useful
• 5:43
  life of their renovation assets from 6 years to 10 years. Oh, okay.
• 5:47
  So if you're looking at your own personal finances, this is essentially like
• 5:52
  refinancing a three-year car loan into a five-year loan.
• 5:55
  That's a perfect analogy. The car is exactly the same.
• 5:58
  You're still driving it to work every day. But because you stretched out the
• 6:02
  timeline, your monthly expense looks much smaller on paper.
• 6:05
  Spot on. In a corporate world, this process is called depreciation.
• 6:09
  By stretching that timeline from 10 to 15 years, this accounting estimate change
• 6:15
  reduced their depreciation expense by $403,000 for the year. Wow.
• 6:20
  So that is almost half a million dollars that simply wasn't subtracted from
• 6:24
  their revenue this year. Right.
• 6:26
  Providing a very nice, completely legal boost to the reported profit.
• 6:30
  Which kind of begs the question of causality, doesn't it? How so?
• 6:34
  Well, did they extend the equipment's lifespan because modern MRI technology
• 6:38
  is genuinely lasting longer in the field?
• 6:41
  Or, you know, did they conveniently change the timeline specifically to buffer
• 6:45
  that 61% spike in financing costs? That is the million-dollar question.
• 6:50
  It is likely a mixture of both.
• 6:53
  Management states the revision better reflect the expected utility of the assets
• 6:57
  based on their maintenance history.
• 6:59
  Sure, they have to say that. Right. But from an investor's perspective,
• 7:02
  it is crucial to recognize that this S-403,000 dollar savings is purely a paper adjustment.
• 7:09
  It's not real cash. Exactly. It improves the look of the income statement,
• 7:13
  but it doesn't actually put a single new dollar into the company's bank account. Right.
• 7:17
  It's brilliant accounting, but it's just math.
• 7:20
  However, while management was tweaking the timeline on their core assets,
• 7:23
  they made a massive surgical cut to a totally different part of the business.
• 7:27
  Yes, the disposal of their aesthetics division. Here's where it gets really interesting.
• 7:31
  In October 2025, Asia Medic disposed of its aesthetic business, which was known as ATAC.
• 7:37
  That's Asia Medic Estique, the aesthetic clinic. A bit of a mouthful.
• 7:41
  Yeah, but they sold a 60% controlling interest in it for just S-150,000 dollars.
• 7:46
  Now, for a publicly listed company, that's $150,000 sounds like absolute pocket change.
• 7:53
  It really is. So why go through the trouble of a whole corporate transaction for that amount?
• 7:59
  Because the upfront cash was only a tiny fraction of the actual financial impact.
• 8:03
  The real value of this deal was complex, but highly rewarding for their balance
• 8:07
  sheet. Okay, walk me through the math.
• 8:09
  So, because they sold the controlling stake, Agent Medic was legally required
• 8:14
  to deconsolidate ATAC from their main financial reports.
• 8:17
  Okay, so because they no longer control it, they basically get to uncouple that
• 8:21
  business's baggage from their own train.
• 8:23
  Precisely. When you own a controlling stake in a subsidiary,
• 8:26
  you must include all of its assets, but critically, all of its liabilities on
• 8:31
  your consolidated financial statements. And ATAC had liability.
• 8:34
  ATAC was actually carrying net liabilities, meaning the clinic owed more than it owned. Oh.
• 8:39
  Yeah. So by dropping their stake to 40%, Asia Medic got to wipe those liabilities
• 8:43
  completely off their books.
• 8:45
  And that removal of debt is recorded as the S1.91 million dollar gain on their income statement.
• 8:51
  So wait, they essentially got paid a premium on paper just for getting rid of a burden? They did.
• 8:57
  However, corporate transactions are rarely that perfectly clean.
• 9:00
  There's a catch. There is.
• 9:02
  As part of this deconsolidation, they also had to recognize a S1.03 million
• 9:08
  dollar impairment loss. On what?
• 9:10
  On a shareholder loan they had previously given to ATAC.
• 9:13
  They are effectively acknowledging to their investors, you know,
• 9:15
  we probably aren't getting that loan money back.
• 9:17
  Ah, OK. But still, when you net the S1.91 million dollar paper gain against
• 9:22
  the S1.03 million dollar loan impairment, the company still walks away with
• 9:27
  a net extraordinary gain. Right.
• 9:29
  About 0.88 million dollars for the year. So between the S-400,000 dollars saved
• 9:33
  from stretching equipment depreciation and the nearly S-900,000 dollars gained
• 9:38
  from offloading the aesthetic clinic's liabilities.
• 9:40
  A massive chunk of this year's doubled profit comes from accounting adjustments
• 9:44
  and strategic divestments.
• 9:46
  Rather than just, you know, seeing more patients in the clinic.
• 9:49
  Exactly. Which is why digging into the financial notes is so revealing. But I will say.
• 9:54
  We shouldn't dismiss the strategic value of this move. Why is that?
• 9:58
  This is classic portfolio optimization.
• 10:01
  The aesthetics industry is highly competitive, it's heavily reliant on marketing,
• 10:06
  and it has really high customer churn. It's just a tough business.
• 10:10
  It is. It is a fundamentally different business model than diagnostic imaging,
• 10:15
  which relies on doctor referrals and sticky B2B relationships.
• 10:19
  Right. So by cutting the aesthetic clinic, management is deliberately sharpening
• 10:23
  its focus entirely on its core healthcare competencies, diagnostic imaging and wellness. Yes.
• 10:30
  But they still kept a 40% associate interest. Oh, right.
• 10:33
  Which means if the clinic eventually turns a profit, Asia Medic still captures
• 10:38
  a slice of the upside. Exactly.
• 10:39
  Without dealing with the daily operational headaches, it is a calculated risk
• 10:43
  that cleans up the balance sheet while maintaining optionality.
• 10:46
  Okay, so let's tie this all back to the core paradox we started with today. The cash issue. Yes.
• 10:51
  We have booming core revenues from the new Novena runway. We have extended equipment
• 10:57
  depreciation, artificially lowering expenses.
• 11:00
  And we have a one-off net gain from selling the aesthetic business.
• 11:04
  All of this resulting in doubled profits. Right. So if it didn't stay in the
• 11:08
  bank vault, where did the cash go?
• 11:10
  Because the balance sheet shows their actual cash reserves dropping from $8.7
• 11:15
  million down to $5.7 million.
• 11:18
  To solve that mystery, you have to bypass the income statement entirely and
• 11:22
  look at the cash flow statement. Okay, what does it say?
• 11:24
  Well, their operating cash flow, which is the actual hard currency generated
• 11:28
  by the business of seeing patients, was incredibly healthy at S3.9 million dollars.
• 11:33
  So the core business is genuinely spinning off cash. It is, but management deployed
• 11:37
  that cash very aggressively.
• 11:39
  So if it didn't stay in the vault, they must have either bought new assets or
• 11:42
  paid off old debts. Actually, they did both.
• 11:44
  First, investing activities consumed S3.0 million dollars. That's a lot. Where did that go?
• 11:50
  A large portion of this was used to purchase new, high-tech medical equipment
• 11:54
  to fuel that Novene expansion.
• 11:57
  But interestingly, they also took some of their idle cash and purchased short-term
• 12:01
  treasury bills. Oh, really? Yeah.
• 12:04
  Earning a safe, risk-free yield on cash that would otherwise just be sitting
• 12:07
  in a checking account is a hallmark of smart treasury management.
• 12:10
  Okay, so that covers the investing side. And what about the debts?
• 12:14
  Right. Financing activities consumed another S3.2 million dollars.
• 12:18
  This cash was used to aggressively pay down the principal and the interest on
• 12:23
  the bank borrowings they originally took on to build the Novena expansion.
• 12:27
  Ah, okay. So they made a ton of cash, but they spent it on paying down their
• 12:31
  obligations and acquiring new assets. Precisely.
• 12:34
  Which means their net assets, like the total value of the company actually grew,
• 12:37
  even if the liquid checking account looks smaller. Exactly right.
• 12:41
  Their net assets increased to S18.1 million dollars.
• 12:45
  The company is objectively larger,
• 12:47
  better equipped, and less burdened by liabilities than it was a year ago.
• 12:51
  Okay, but if you are an investor holding shares in Asia Medic,
• 12:54
  a bigger, more valuable company with doubled profits naturally leads to one
• 12:59
  big question. I know what you're going to ask. Where is the dividend?
• 13:02
  Do shareholders get a check to celebrate this record year? This is where the
• 13:07
  sober reality of corporate finance sets in.
• 13:10
  No dividend was declared for FY 2025. None at all, even after doubling profits
• 13:15
  and clearing out the aesthetics liabilities. None.
• 13:18
  And the reason is hidden in plain sight on the balance sheet under a line item
• 13:22
  called accumulated losses. Accumulated losses. Yeah.
• 13:25
  Over the past years, long before this current boom, the company went through leaner times.
• 13:31
  And they accumulated historical losses totaling $16.8 million.
• 13:35
  $16.8 million. Wow. So they have past financial scars they are still healing from. Precisely.
• 13:41
  Under standard accounting rules and prudent corporate governance,
• 13:43
  a company generally needs to clear out those historical accumulated losses before
• 13:48
  it can start legally distributing cash dividends to shareholders.
• 13:51
  That makes a lot of sense. So management is intentionally keeping their powder dry.
• 13:55
  They're conserving their cash to service their remaining debt.
• 13:59
  Fund their day-to-day working capital in a high-cost environment,
• 14:02
  and continue their expansion without needing to borrow more money.
• 14:06
  You know, I have to admit, if you are a retail investor, it might be pretty
• 14:09
  frustrating not to get a yield on your shares this year. Oh, absolutely.
• 14:12
  But looking at the horizon, hoarding that cash and keeping that powder dry isn't
• 14:17
  just a defensive move, it's entirely necessary.
• 14:20
  Because the macro environment they're operating in is a complex mix of incredible
• 14:25
  opportunities and severe challenges. If we connect this to the bigger picture,
• 14:29
  the tailwinds in Singapore are undeniable.
• 14:32
  You have a rapidly aging population, a sweeping national awareness of prevented
• 14:36
  health care, and government initiatives pushing for the early detection of chronic illnesses.
• 14:40
  It's the perfect storm for a diagnostics company. It is.
• 14:44
  Furthermore, FY2026 will be the first time Asia Medic sees a full 12-month financial
• 14:50
  contribution from the fully expanded Novena Diagnostic Center.
• 14:53
  So the demographics of Singapore are essentially guaranteeing a line out the
• 14:58
  door for MRI and x-ray services.
• 15:00
  But, I mean, it can't be all smooth sailing. What are the headwinds pushing
• 15:04
  back against that growth?
• 15:06
  The primary risks are entirely operational. The healthcare industry is facing
• 15:11
  severe, ruthless competition for skilled professionals. Like doctors and nurses.
• 15:16
  Doctors, nurses, and specifically radiographers.
• 15:19
  There is a real manpower shortage across the medical sector,
• 15:22
  which naturally leads to escalating labor costs.
• 15:25
  Right, because having stand-of-the-art diagnostic machines is useless if you
• 15:28
  cannot afford or simply cannot find the people to operate them.
• 15:32
  Exactly. And there was a specific operational setback mentioned in the sources
• 15:36
  that really highlights the vulnerability of their business model.
• 15:39
  Asia Medic actually lost the tender for the Health Promotion Board,
• 15:42
  the HPB School Health Training Project, in late 2025.
• 15:46
  Which is a significant blow to their primary health care segment.
• 15:49
  Yeah, losing a government contract always hurts.
• 15:51
  It does. Because government tenders, like the HPB Project, provide a beautiful,
• 15:57
  predictable baseline of volume.
• 15:59
  You know exactly how many schools you are visiting, you know the margins,
• 16:03
  and you can staff your teams accordingly. And now that's gone.
• 16:06
  Right. Losing that contract means management is acknowledging a guaranteed drop
• 16:11
  in revenue from that specific segment for the upcoming year.
• 16:14
  Which forces them to pivot.
• 16:16
  The report states they are now hunting for alternative corporate screening engagements
• 16:20
  to fill that revenue gap.
• 16:22
  Which is not easy. No, because selling B2B business-to-business is a completely
• 16:26
  different beast than servicing a government contract.
• 16:29
  Very different. You need a dedicated sales team, you have higher customer acquisition
• 16:33
  costs, and corporate contracts are kind of piecemeal compared to a sweeping government mandate.
• 16:38
  It requires an incredibly disciplined and agile management team to navigate
• 16:43
  that transition. You have to secure those corporate contracts quickly while
• 16:46
  simultaneously managing the escalating costs of your core imaging staff.
• 16:51
  Right. So to pull all of this together for you, AsiaMedic's financial picture
• 16:55
  is a really delicate balancing act.
• 16:57
  It is. On one side, you have almost unstoppable demographic tailwinds and aging
• 17:03
  population that absolutely needs these diagnostic services matched with a newly
• 17:08
  expanded facility ready to capture that demand.
• 17:10
  But on the other side, you have fierce operational headwinds,
• 17:14
  a tight labor market making it increasingly expensive to provide those services,
• 17:19
  and the constant pressure of replacing lost government tenders with corporate sales.
• 17:25
  It is a company that has successfully transitioned from building its infrastructure
• 17:29
  to operating it, but now faces the grueling task of optimizing those operations
• 17:34
  in a high-cost environment. Which brings us back to that strategic decision we discussed earlier.
• 17:40
  AsiaMedic strategically amputated its aesthetics business, just as the demographic
• 17:44
  thesis for aging population health care is proving highly profitable for their
• 17:49
  imaging centers. That's a very deliberate choice.
• 17:51
  But it makes you wonder about the long-term mechanics of this specific business model.
• 17:55
  If extending the useful life of an MRI machine from 10 to 15 years is what it
• 17:59
  takes to look highly profitable on paper today, what happens in 2035 or 2040?
• 18:04
  When the machines get old.
• 18:05
  Right. When all of this extended technology inevitably ages out simultaneously,
• 18:11
  right at the peak of the demographic boom,
• 18:13
  Are we looking at a golden era of health care profitability or a ticking capital
• 18:18
  expenditure time bomb for these providers?
• 18:20
  It really makes you wonder, in the future of the medical industry,
• 18:23
  will the most successful health care providers be defined less by the services
• 18:27
  they offer and more by the lucrative distractions they have the discipline to say no to?
• 18:31
  This content is intended to serve strictly and only as an informational,
• 18:35
  independent, objective summary of recent events and should in no way be interpreted,
• 18:40
  construed or relied upon by any party as inside information or financial advice.